期刊
JOURNAL OF TRANSLATIONAL MEDICINE
卷 12, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/s12967-014-0338-3
关键词
Dendritic cells; Vaccine; Lymphocytes; Immunogenicity; Cancer; Adjuvant
资金
- Dextra Baldwin McGonagle Foundation, Inc.
- Emerald Foundation, Inc.
- Sohn Foundation
- National Center for Advancing Translational Science
- Clinical and Translational Science Award Program [8 UL1 TR000043]
- National Institutes of Health
- Rockefeller University Center for Clinical and Translational Science [KL2 TR000151]
- Beth and Ravenel Curry Clinical Scholarship
Background: Dendritic cells are currently under investigation for their ability to generate anti-cancer immune responses. No consensus has been reached as to the optimal method of dendritic cell vaccine preparation and is a barrier to success in the field. Methods: Over a course of three separate dendritic cell vaccine studies to treat cancer, we tested two different methods for preparing dendritic cells from peripheral blood mononuclear cells: adherence and antibody-selected CD14+ cells. Results: Surprisingly, we found that patients who received dendritic cell vaccines generated by the adherence method mounted increased T cell proliferation in response to vaccination. This difference could not be accounted for by dendritic cell vaccine dose, cell surface phenotype or dendritic cell function in vitro. One notable difference between the two vaccine preparation methods was that the dendritic cell vaccine cultures generated by the adherence method contained up to 10% lymphocytes, and these lymphocytes were proliferating and producing IFN gamma in response to antigen in vitro at the time of administration. Conclusions: Enhanced immunogenicity of adherence dendritic cell vaccinations may be due to the presence of lymphocytes during dendritic cell culture.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据